DDR2 G253C

CI-VAR-00001683Explore in graph →ENST00000367922.3:c.757G>TClinVar 376142 CIViC 141

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
DDR2 G253C	Dasatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID266 Ba/F3 cells expressing the G253C mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.